|Table of Contents|

Relationship between the expression of PD-1/PD-L1 and EGFR mutation in non-small cell lung cancer and its effect on prognosis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 21
Page:
3963-3967
Research Field:
Publishing date:

Info

Title:
Relationship between the expression of PD-1/PD-L1 and EGFR mutation in non-small cell lung cancer and its effect on prognosis
Author(s):
DENG Xiaoxu; YANG Xianghong
Department of Pathology,Shengjing Hospital of China Medical University,Liaoning Shenyang 110000,China.
Keywords:
non-small cell lung cancer; programmed death receptor 1(PD-1); programmed death receptor ligand 1(PD-L1); CD8; prognosis
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2023.21.011
Abstract:
Objective:To study the prognostic significance of programmed death receptor-1(PD-1),programmed death receptor ligand-1(PD-L1)with EGFR mutation in predicting non-small cell lung cancer(NSCLC) patients’ survival time.Methods:The clinical data of 150 patients with histologically diagnosed NSCLC who complete EGFR mutation detection in our hospital from January 2013 to December 2015 were collected.The expressions of PD-1/PD-L1 and CD8 proteins in NSCLC tissues were detected by immunohistochemistry.The correlation between EGFR mutation and clinicopathological parameters were analyzed,with the clinicopathological factors affecting the prognosis of patients.Results:The positive expression rates of PD-1/PD-L1 and CD8 in NSCLC tissues were 34.7%(52/150),50.4%(57/113) and 59.2%(84/142),respectively.The expression of PD-L1 was correlated with the expression of PD-1(P=0.025,Spearman correlation coefficient 0.211).The expression of PD-1 was correlated with postoperative pathological stage(P=0.031,Spearman correlation coefficient -0.177),EGFR mutation(P=0.001,Spearman correlation coefficient -0.257) and CD8 expression(P=0.000,Spearman correlation coefficient 0.323).The expression of CD8 was correlated with histological type(P=0.048,Spearman correlation coefficient 0.173).Follow-up of NSCLC patients showed that the overall survival of patients with moderate-poorly differentiated tumors,clinical stage Ⅳ,distant metastasis and high PD-1 expression were significantly lower than those with highly differentiated tumors,clinical stage I-III,no distant metastasis and low PD-1 expression(P<0.05).Conclusion:PD-1/PD-L1 and CD8 are involved in the pathological process of NSCLC.The expression of PD-1 is related to the postoperative pathological stage and EGFR mutation status of patients with NSCLC,which affects the prognosis of patients.

References:

［1］XIA CF,DONG XS,LI H,et al.Cancer statistics in China and United States,2022:profiles,trends,and determinants［J］.Chinese Medical Journal,2022,135(5):584-590.
［2］General Office of the National Health Commission.Guidelines for diagnosis and treatment of primary lung cancer (2022 edition) ［J］.Union Medical Journal,2022,13(4):549-570.
［3］GANTI AK,KLEIN AB,COTARLA I,et a1.Update of incidence,prevalence,survival,and initial treatment in patients with non-small cell lung cancer in the US［J］.JAMA Oncol,2021,7(12):1824-1832.
［4］RECK M,GUEZ-ABREU DR,ROBINSON AG,et a1.Updated analysis of KEYNOTE-024:pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater［J］.J Clin Oncol,2019,37(7):537-546.
［5］MAZIERES J,DRILON A,LUSQUE A,et al.Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations:results from the immunotarget registry［J］.Ann Oncol,2019,30(8):1321-1328.
［6］UEDA K,SUEKANE S,KUROSE H,et al.Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma［J］.Urol Oncol,2018,36(11):499.
［7］JEANETTE EE,THAI HH,DANIEL JS,et al.Concordance of PD-1 and PD-L1(B7-H1) in paired primary and metastatic clear cell renal cell carcinoma［J］.Cancer Med,2020,9(3):1152-1160.
［8］FELIP E,ALTORKI N,ZHOU CC,et al.Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-ⅢA non-small-cell lung cancer(IMpower010):a randomised,multicentre,open-label,phase 3 trial［J］.Lancet,2021,398(10308):1344-1357.
［9］YAO YX,XIA LL,WANG H,et al.Role of peripheral monocytes in the therapeutic evaluation of anti-PD-L1 treatment in non-small cell lung cancer［J］.Modern Oncology,2021,29(24):4316-4323.
［10］MAZZASCHI G,MADEDDU D,FALCO A,et al.Low PD-1 expression in cytotoxic CD8 tumor-infiltrating lymphocytes confers an immune-privileged tissue microenvironment in NSCLC with a prognostic and predictive value［J］.Clin Cancer Res,2018,24(2):407-419.
［11］JIANG L,LIN ZY,LI N,et al.Correlation study on expression of PD-1 and PD-L1 in non-small cell lung cancer and epidermal growth factor receptor mutations［J］.Chinese journal of Lung Cancer,2021,24(9):623–631.
［12］KOUKOURAKIS IM,GIATROMANOLAKI A,MITRAKAS A,et al.Loss of HLA-class-I expression in non-small-cell lung cancer:association with prognosis and anaerobic metabolism［J］.Cell Immunol,2022,73:104495.
［13］SANTARPIA M,KARACHALIOU N.Tumor immune microenvironment characterization andresponse to anti-PD-1 therapy［J］.Cancer Biol Med，2015,12(2):74-78.
［14］MITTAL D,GUBIN MM,SCHREIBER RD,et al.New insightse into cancer immunoediting and its three component phases-elimination,quilibrium and escape［J］.Curr Opin Immunol,2014,27:16-25.
［15］JIANG XJ,WANG J,DENG XY,et al.Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape［J］.Mol Cancer,2019,18:10.
［16］CHEN J,JIANG CC,JIN L,et al.Regulation of PD-L1:a novel role of pro-survival signalling in cancer［J］.Ann Oncol,2016,27(3):409-416.
［17］MANSFIELD AS,MURPHY SJ,PEIKERT T,et al.Heterogeneity of programmed cell death ligand 1 expression in multifocal lung cancer［J］.Clin Cancer Res,2016,22(9):2177-2182.
［18］MCLAUGHLIN J,HAN G,SCHALPER KA,et al.Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer［J］.Jama Oncol,2016,2(1):46-54.
［19］CARBONE DP,RECK M,PAZ-ARES L,et al.First-line nivolumab in stage Ⅳ or recurrent non-small-cell lung cancer［J］.N Engl J Med,2017,376(25):2415-2426.
［20］BRAHMER J,RECKAMP KL,BAAS P,et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer［J］.N Engl J Med,2015,373(2):123-135.
［21］ESTEBAN-RODRGUEZ I,BRAVO-BURGUILLOS ER,ROSAS R,et al.Protein expression of PD-L1 and clinico-pathological data in a cohort of 53 patients with resectable non small cell lung cancer(NSCLC).Concordance between clones(22C3 and 28-8) and observers.Correlation and prognostic value of clinico-pathological data［J］.Rev Esp Patol,2020,53(1):10-18.

Memo

Memo:
-
Last Update: 2023-09-28